In a year marked by war, political upheaval, and global economic volatility, Israel’s tech sector continues to defy the odds — and the Technion is once again at the heart of its resilience. Three of the standout companies on Calcalist’s 2025 list of the 50 most promising Israeli startups — Decart, ForSight Robotics, and OX Security — all trace their roots to the Technion, where bold ideas and deep scientific training are shaping real-world solutions. These startups aren’t just succeeding; they’re changing the game across AI, healthcare, and cybersecurity.

Decart: Accelerating the Generative AI Revolution

Just 18 months after its founding, Decart has raised $53 million, earned a half-billion-dollar valuation, and captured the attention of top-tier venture firms like Sequoia Capital and Benchmark. At its core is a powerful systems-level AI infrastructure that enables a tenfold improvement in training and inference speed for large generative models, unlocking real-time AI applications previously limited to tech giants.

The company’s momentum is fueled by deep academic and technical foundations. Technion alumnus Dean Leitersdorf, Decart’s CEO and co-founder, launched the company with fellow co-founder Moshe Sason during a period of reserve duty — building their team and vision under extraordinary pressure. Their platform dramatically reduces the resource load of generative AI, allowing them to train and deploy their own foundational models. It’s a leap forward in making powerful AI not only faster and cheaper, but more accessible to companies and creators around the world.

ForSight Robotics: Precision Eye Surgery for a World in Need

More than 2 billion people worldwide suffer from vision impairment, but there aren’t nearly enough trained eye surgeons to meet the growing demand. ForSight Robotics aims to bridge that gap with a robotic microsurgery platform that delivers 10x the accuracy of a human hand. Their technology integrates robotics, machine learning, and computer imaging to perform delicate eye procedures with unprecedented precision, starting with cataract surgery.

The company was co-founded by Technion alumnus and company President and Chief Medical Officer Dr. Joseph Nathan. A practicing ophthalmologist and engineer, Dr. Nathan helped launch ForSight alongside Technion Professor Moshe Shoham, a pioneer in medical robotics and founder of Mazor Robotics. Together with CEO Dr. Daniel Glozman, they’ve built a platform with the potential to democratize surgical care, especially in regions with limited access to specialists. With the world’s aging population and rising chronic disease rates, ForSight’s mission is not just to enhance surgical performance, but to make sight-saving procedures globally scalable.

OX Security: Cutting Through the Noise in Cyber Defence

In today’s cybersecurity landscape, overwhelmed teams are bombarded with alerts — many of them low-risk. OX Security takes a radically different approach, focusing only on the small percentage of vulnerabilities that could truly cripple a business. That philosophy, born in the wake of the SolarWinds hack, has resonated strongly with customers and investors alike. Since emerging from stealth in 2022 with a $34 million Seed round — one of the largest in Israeli cybersecurity history — OX Security has quickly amassed hundreds of paying clients.

The company was founded by Technion alumnus Neatsun Ziv, former VP of Threat Prevention at Check Point, alongside CPO Lior Arzi. Both are Unit 8200 veterans and cybersecurity experts with decades of combined experience. Their mission is to cut through the noise, reduce alert fatigue, and help organizations defend themselves more effectively against the threats that truly matter. With most of its early competitors already acquired, OX Security is now a standout in a space that demands clarity, speed, and precision.

Together, Decart, ForSight Robotics, and OX Security reflect the Technion’s role as a launchpad for ideas that matter — and for startups built not just to survive disruption, but to lead through it.

Outstanding Achievements for the Israeli Chemistry Team Trained at the Technion

The Israeli National Chemistry Team has won four Olympic medals — two gold and two silver — at the International Chemistry Olympiad held in the United Arab Emirates, with participation from 90 countries.

At the International Chemistry Olympiad (IChO), held this year in the UAE, 354 competitors from 90 countries around the world took part. The Israeli Chemistry Team proudly representing Israel:

  • Itamar Ben Shmuel – from Ramat Gan, 11th-grade student at the Kfar HaYarok School – Gold Medalist
  • Jonathan Gontmakher– from Rishon LeZion, 12th-grade student at the Krieger Real Gymnasium – Gold Medalist
  • Omer Zachary Ben-Ami – from Tel Aviv, 12th-grade student at Ironi Dalet High School – Silver Medalist
  • Yehonadav Marienberg – from Mazkeret Batya, 10th-grade student at the Har Etzion Yeshiva High School for Youth, Alon Shvut – Silver Medalist

The Ministry of Education and the Maimonides Fund’s Future Scientists Center lead the preparation of Israel’s national science teams for participation in international olympiads. The Israeli Chemistry Team was trained at the Schulich Faculty of Chemistry at the Technion, led by Academic Director Prof. Zeev Gross and Head Coach Dr. Reut Shapira. Accompanying the delegation were Prof. Gross, Dr. Eyal Barnea, and Dr. Zack Patrick Sarcel.

Minister of Education, Yoav Kisch: “Behind every medal stands an Israeli student with a spark in their eyes, curiosity in their heart, and a willingness to work hard – children like Itamar, Jonathan, Omer, and Yehonadav, who dared to dream big and saw it through to the end. Each one of them represents a story of persistence, talent, and educational support that believes in the student every step of the way. The achievement at the Chemistry Olympiad is not just a peak – it’s the result of daily quiet effort, a deep partnership between the Ministry of Education, the Maimonides Fund’s Future Scientists Center, and the Technion, and teams who never stop seeing the child, even when immersed in science. This is how we build an education system that moves forward: not waiting for success, but growing it. With consistency, humility, and deep faith in our children’s abilities.”

Technion President, Prof. Uri Sivan, thanked the Technion team that trained the delegation and said: “At the Technion, we are proud to train the next generation of Israeli scientists. The students competing in the International Chemistry Olympiads undergo screening and preparation in a special program that has been running for years at the Schulich Faculty of Chemistry at the Technion, under the direction of Prof. Zeev Gross. Winning the international competition is a major achievement. Jonathan, Itamar, Omer, and Yehonadav – I congratulate you. You reached the competition after much effort and have proven your excellence. I hope to see you in the future as students at the Technion – fulfilling your potential and bringing us academic pride.”

The Technion has once again proven its standing as a world-class institution, in the newly released Shanghai Ranking (ARWU). The index shows that the Technion was ranked 12th among technological universities in the world.

When academic achievements are adjusted for university size – comparing relative output to the number of faculty members – the Technion is ranked 28th worldwide out of all Universities.

The Technion also ranks highly in the prize-related categories of the index, which are based on Nobel Prize and Fields Medal wins – 25th in the world for faculty members and 55th for alumni.

The Shanghai Ranking is the world’s leading index for ranking higher education institutions, and since 2012 (except 2020), it has consistently placed the Technion in its Top 100 list, with rankings ranging between 69 and 97.

The Shanghai Ranking, published since 2003, evaluates the research level of universities worldwide according to various criteria, including the number of Nobel Prize and Fields Medal laureates among faculty and alumni, the number of scientific articles published in the leading journals Nature and Science, and other research performance indicators. The ranking covers more than 2,500 universities, with the publication listing the top 1,000. This year’s ranking is headed by Harvard University, followed by Stanford University and MIT.

Technion team discover proteins in human breast milk can help deliver sensitive medical compounds, such as vaccines and insulin, through digestive system into bloodstream

Technion Prof. Assaf Zinger is working to make medications and vaccines more accessible by allowing people to take them in liquid form rather than by injection. The concept is based on how breastmilk delivers sensitive compounds directly into the bloodstream via the digestive system, which his team aims to replicate. They plan to combine nanoparticles and breast milk proteins, which they believe could develop into “taxis” to transport drugs, vaccines, and other vital compounds into the bloodstream. Such a breakthrough could help prevent and treat conditions such as inflammation, diabetes, infections, cancer, and malnutrition, significantly improving patient care, particularly for those with chronic or acute illnesses. Their study was recently published in the Journal of Controlled Release.

Imagine a world where antibodies, proteins such as insulin, and even COVID-19 and flu vaccines could be consumed orally instead of injected. This vision is closer than ever. The fundamental idea is to make medications and vaccines more accessible by allowing people to take them in liquid form rather than by injection.

The inspiration for this research came from home—literally. Dr. Asaf Singer, a researcher at the Technion-Israel Institute of Technology, observed his wife, Noa, breastfeeding their two daughters. He wondered how breast milk could naturally deliver so many essential substances to infants. 

The deeper he delved into the topic, the more he realized that breast milk is far more than just nutrition—it is a sophisticated biological transport system capable of something that medicine has long struggled with: delivering sensitive compounds directly into the bloodstream via the digestive system. This is exactly what his research team aims to replicate.

Their study was recently published in the Journal of Controlled Release under the title: “Harnessing the Potential of Human Breast Milk to Enhance Intestinal Permeability for Nanoparticles and Macromolecules.” Conducted in collaboration with two Technion faculties, the research highlights the importance of interdisciplinary cooperation.

The Secret of Breast Milk

Breast milk is a remarkable fluid containing a wide range of essential components. To affect an infant’s health, these substances must pass from the digestive system into the bloodstream. This requires crossing biological barriers, including the intestinal barrier—a large membrane separating the inside of the gut from the circulatory system. The body typically distinguishes between beneficial and harmful substances, which is why some oral medications fail to reach their intended targets. However, breast milk contains special proteins that “convince” the body to let them pass.

Doctoral student Si Naftaly, who co-led the study with Singer, posed a crucial question: If substances in breast milk can cross this barrier, then the milk must contain “keys” that enable them to do so. What are these keys? To investigate, the researchers compared human breast milk, cow’s milk, and infant formula. Breast milk demonstrated the highest permeability through the intestinal barrier.

To conduct the research, a significant supply of breast milk was needed. Due to the October 7 attack and its aftermath, breast milk donations in Israel were directed toward orphans. As a result, the research team turned to mothers at the Technion to collect donations for the study.

How Does It Work?

The study uncovered a key mechanism: a natural protein coating from breast milk, termed Human Breast Milk Protein Corona, which facilitates the passage of nanoparticles (ultra-small particles) through the intestinal wall. This discovery was confirmed in both human intestinal cells and pig intestines, which closely resemble human digestive physiology.

Breast milk serves as the primary, and sometimes only, source of nutrition for infants. It is a complex and dynamic liquid that adapts to a baby’s needs, supplying enzymes, growth factors, hormones, antibodies, nucleic acids, extracellular vesicles, carbohydrates, lipids, vitamins, minerals, proteins, and cells. These components are crucial for the development of various bodily systems. Unlike infant formula, which is uniform in composition, breast milk varies based on numerous factors related to the mother. Awareness of its medical value has grown in recent years, and it is now recognised as a natural remedy for various diseases, particularly those affecting the intestines.

The study provides a solution for delivering nanoparticles and molecules from the digestive system to the bloodstream. Based on these findings, the next step is an engineering and applied research phase—developing nanoparticles that mimic this mechanism, ensuring their successful passage through the intestinal barrier. These nanoparticles could carry various medical payloads, including RNA vaccines, proteins, and contrast agents for imaging. Their protective properties help shield medical compounds from the harsh conditions of the digestive system, making them a promising drug delivery method.

What Does This Mean for the Future of Vaccines?

By combining two natural elements—nanoparticles and breast milk proteins—the researchers believe they can develop tiny “taxis” to transport drugs, vaccines, and other vital compounds into the bloodstream. This concept could revolutionize medicine by replacing injections with orally administered treatments. Such a breakthrough could help prevent and treat conditions such as inflammation, diabetes, infections, cancer, and malnutrition, significantly improving patient care, particularly for those with chronic or acute illnesses.

The study was led by Dr. Asaf Singer and doctoral student Si Naftaly, along with Prof. Maya Davidovich-Pinhas from the Faculty of Biotechnology and Food Engineering at the Technion, and four additional students from the Faculty of Chemical Engineering and the Faculty of Biotechnology and Food Engineering. 

It was supported by the Israel Science Foundation, the Israel Cancer Research Fund, the Stuart & Linda Resnick Sustainability and Catalysis Institute at the Technion, the Russell Berrie Nanotechnology Institute, the Bruce & Ruth Rappaport Cancer Research Institute, the Alon Fellowship, the Noam Seiden Fellowship in Nanotechnology and Optoelectronics, and the European Research Council’s “Milkosomes” grant.

Odysight.ai’s technology allows for constant monitoring of aircraft, sending alerts in case of malfunctions that could lead to accidents.

Israeli company Odysight.AI is working to reduce airplane accidents and make aviation safer. Odysight’s AI-based visual sensing technology monitors the conditions and critical safety components of hard-to-reach environments, such as planes, for the early detection of potential malfunctions that could lead to accidents. The system sends out an alert anytime it detects an anomaly. In addition to improving safety, the system significantly reduces maintenance costs and labor. The company has offices in Israel and the United States and plans to open bureaus in Europe this year. Odysight.AI CTO Eli Israeli is a Technion alumnus.

News reports over the past year indicate that airplane accidents are increasing. 

According to a report from the International Air Transport Association (IATA), the number of fatal air accidents in 2024 rose to seven with 244 fatalities, compared to 2023’s one fatal accident that resulted in 72 deaths. 

The data does not include deaths from security-related aviation incidents such as the crash of an Azerbaijan Airlines jet — allegedly brought down by a Russian missile — that killed 38 people.  

In the report, the IATA described the increase as “a top concern for aviation safety requiring urgent global coordination.”

Odysight.ia

Now, Israeli company Odysight.ia (a combination of the words “odyssey,” “sight” and “artificial intelligence”) is working to reduce airplane accidents and make aviation generally safer. 

“We are changing the aviation world,” Odysight’s CEO, Col. (ret.) Yehuda Ofer, an entrepreneur and ex-Israeli Air Force pilot. 

Odysight’s AI-based visual sensing technology monitors the conditions and critical safety components of hard-to-reach environments, such as planes, for the early detection of potential malfunctions that could lead to accidents. 

Anytime the system detects an anomaly, it sends out an alert. The system is essentially a kit — a small, advanced computer with a set of specialized sensors, unique operating system, and levels of visual analytics and algorithms technologies.

“Our algorithm creates not only an alert in real time for the anomaly, but also a prediction, which is a crucial part of the technology. If you can see things that are there, but normally cannot be monitored, you have very valuable data for all the chain of maintenance,” says Ofer.

Alongside increasing safety, the system is said to significantly reduce maintenance costs and labor. “The most expensive thing in aviation for an aircraft is time on the ground” to carry out safety procedures, notes Ofer. 

Odysight also lowers costs because fewer maintenance personnel are required and the system can be more reliable than human employees, who are less and less inclined to go into this profession. 

“Our system does not go out for the weekend, does not drink, does not have a girlfriend; it is just there, watching and monitoring all the time,” adds Ofer.

From health to NASA

Founded in 2013 under the name ScoutCam, the company’s technology was initially developed for medical use to treat gastrointestinal disorders and perform minimally invasive surgeries. 

It was established by Prof. Benad Goldwasser, a veteran Israeli urological surgeon and a founder of several successful medical startups. 

In 2020, the company changed its name and pivoted its focus from health to aviation after the IAF approached the startup, asking for a potential solution following a helicopter accident that resulted in a crash. 

Odysight is still involved in the medical field, but “it’s not our main focus,” says Ofer, who has been with the company since 2022. 

Since pivoting, Odysight’s technology has been used by NASA in its Robotic Refuelling Mission 3.

“It’s a robot that goes outside of the space shuttle and attaches to a dead satellite in orbit, checking the fuel systems. If everything is okay — no cracks, no leaks — you can refuel the dead satellite,” explains Ofer.

Pioneers

Ofer says the big vision for the company is to expand and become the sector leader. “We are already pioneers, and we want to create a better and safer world,” he says.

Odysight recently became the first Israeli startup to announce an initial public offering in 2025, uplisting to Nasdaq with an IPO priced at $21.5 million at a company valuation of $129 million. 

“We raised the funds that are required, as well as sales and backlog,” adds Ofer.

The company employs 60 workers across its offices in Israel and the United States, and plans to open bureaus in Europe this year. 

One of the Israeli offices is located in Omer, some 40 km (25 miles) from Gaza in southern Israel. 

“We have people here from different industries and backgrounds, who never stopped working throughout the war, not even for one day,” Ofer tells. 

“The best of technologies cannot go forward from being a vision to a real capability without the people who are making the difference. It’s the people that push us forward.”

With the outbreak of the war, the Technion established an unprecedented support system to assist reservist students in all aspects of life during this time

The Technion – Israel Institute of Technology will be awarded the Defense Minister’s Shield for 2025 in recognition of its outstanding support for military reservists. The Shield is granted to organizations and institutions that have demonstrated exceptional commitment to reservists and aims to honor their support for employees and students serving in the reserves. It also raises awareness of their contributions to society and the security of the State. The award will be presented to the Technion at the Reserves Appreciation Ceremony on May 28, in the presence of Defense Minister Israel Katz, IDF Chief of Staff Eyal Zamir, and Chief Reserve Officer Brigadier General (res.) Benny Ben Ari.

Since the beginning of the Swords of Iron War, thousands of Technion students have been called up for reserve duty under emergency order, alongside many members of the academic, administrative, and teaching staff. Among these students, more than 1,000 have served more than 150 days in the past year, and more than 500 have served more than 250 days. Since the war’s outbreak, the Technion has provided an extensive personal support system, including academic accommodations, tutoring, one-on-one mentoring, emotional support, and financial assistance, all made possible with the help of friends in Israel and around the world.

“We are proud and honored to receive this award,” saidTechnion President Prof. Uri Sivan. “The Technion bears a historic responsibility toward Israeli society, its security, and its economy, along with a deep commitment to the Technion family. The Defense Minister’s Shield is a recognition of the tremendous effort the Technion invests in supporting its reservists. Above all, it expresses our gratitude to the academic and administrative staff and to the thousands of students who leave everything behind to report for reserve duty.”

Senior Executive Vice President Prof. Oded Rabinovitch added: “Our commitment to students serving in the reserves is deep, based on our values, and embedded in the Technion’s essence. Just as our students step up to serve, the entire Technion community stands behind them. For us, it is a great honor. From the very first hours of the war, we made it our mission to reach out to every reservist and provide whatever support was needed, achieving an almost zero dropout rate. We are proud of our students and of the hundreds of Technion faculty and staff members who do everything in their power to help them succeed.

The support system established by the Technion has proven itself. It was the basis for the development of the national academic accommodations framework for reservist students, which was adopted by all public universities and colleges in Israel. Our commitment to reservists will continue—it is an integral part of who we are as a Technion community.”

Haifa-based Pluri entered into an exclusive collaboration with Ukrainian umbilical cord blood bank Hemafund last month to stockpile and distribute its placental expanded cell therapy, PLX-R18, as a potential treatment for life-threatening radiation sickness. Under the terms of the collaboration agreement with Hemafund, Pluri will produce and supply an initial capacity of 12,000 doses of its PLX-R18, sufficient to treat 6,000 people. Pluri was founded in 2001 by Technion alumnus Shai Meretzki, who made use of a stem cell patent developed during his Ph.D. studies in the Rappaport Faculty of Medicine

Amid rising threat from Russia, Pluri partners with Ukrainian blood bank to stockpile remedy for deadly radiation poisoning that uses cells grown from donated placentas.

About two weeks after a Russian drone struck the cover built to contain radiation at the Chernobyl nuclear power plant, Israeli biotech firm Pluri, a developer of placenta-based cell technology, landed an agreement to help Ukraine develop an emergency response to life-threatening radiation sickness in case of a radiological event.

The nearly three-year war between Russia and Ukraine has underscored the ever-rising threat of nuclear fallout amid repeated shelling of a nuclear power plant in southern Ukraine and Russian President Vladimir Putin’s threat to use nuclear weapons.

Last month, Haifa-based Pluri (formerly Pluristem) entered into an exclusive collaboration with Ukrainian umbilical cord blood bank Hemafund to stockpile and distribute its placental expanded cell therapy, PLX-R18, as a potential treatment for life-threatening radiation sickness.

The condition, also known as hematopoietic acute radiation syndrome (H-ARS), occurs when a person is exposed to high levels of ionizing radiation, such as during a nuclear attack or accident. Destruction of the bone marrow and blood cells ensues, leading to severe anemia, infection and bleeding.

Death can occur in four to eight weeks if effective treatment is not received.

Over the past two decades, Pluri has focused on developing 3D technology to mimic how living cells communicate and interact with the body to grow and expand. The biotech firm harnesses stem cells extracted from placenta donated by healthy women who have given birth by cesarean section in hospitals around the country. The single placenta cells are cultivated in a proprietary 3D bioreactor system with a micro-environment that resembles and simulates the human body.

“Cells are the building blocks of life — everything in our world starts and ends with cells,” Pluri chief commercial officer Nimrod Bar Zvi told The Times of Israel. “These tiny cells are amazing creatures that exist in almost any aspect of our life, whether we get them from humans, animals, or plants.”

Bar Zvi explained that once placed inside bioreactors, the stem cells latch onto scaffolds and start “to communicate with each other and proliferate, similar to what happens in the human body, and they are secreting proteins as we mimic the conditions of the natural environment they need to expand.”

Using the 3D cell expansion technology method, a single placenta cell can be multiplied into billions of distinct cells, Pluri said. As a result, cells from a single placenta can treat more than 20,000 patients.

“In the end of that process, we have a vial that contains a specific amount of our placental expanded cells depending on the dosage needed for the patient,” said Bar Zvi. “Once the vial with the cells is injected into the muscle, it stimulates the human body’s own capabilities for the reactivation and regeneration of blood cells, mitigates the effects of radiation exposure and we see the recovery happening.”

Pluri says that its cell-based treatment stimulates and regenerates the production of all three types of blood cells produced in the blood marrow: white and red blood cells as well as platelets.

Under the terms of the collaboration agreement with Hemafund and subject to receiving external government and private sector funding, the veteran biotech firm will produce and supply an initial capacity of 12,000 doses of its PLX-R18, sufficient to treat 6,000 people. The doses will be stored and managed by Hemafund and delivered to medical institutions across Ukraine in case of need.

“At present, there are no other treatments for radiation poisoning that use stem cells taken from a placenta as far as we know,” said Bar Zvi. “The ability to treat acute radiation exposure with cell therapy and to scale it up for mass production is where we are unique since we can supply thousands and thousands of vials to large numbers of people.”

Pluri is publicly traded on the Nasdaq as well as the Tel Aviv Stock Exchange. At the Matam Advanced Technology Park in Haifa, the biotech firm operates a cell therapy production facility, which it says has been designed to handle large-scale manufacturing of cellular therapies. It could also be mobilized for mass production to respond to global emergencies if nuclear threats escalate. The firm employs a total of 130 people.

Pluri and Hemafund said they will also seek to advance clinical trials to register the PLX-R18 therapy as a radiation countermeasure and obtain necessary regulatory approvals from Ukraine’s health ministry. The collaboration is expected to potentially generate over $100 million in value for both parties.

“Our cryostorage facilities and logistics network position us well to support the introduction of PLX-R18 as a potential vital tool for radiation emergency preparedness in Ukraine,” said Hemafund founder Yaroslav Issakov. “While we hope such treatments remain precautionary, our goal is to stand ready to distribute this potential therapy in the event of an emergency.”

Pluri uses patented technology to create cell-based pharmaceutical and food products. (Courtesy)

Pluri said that its PLX-R18 has been safely tested in both humans and animals. Results from a series of recent studies in animals of its stem cell therapy after radiation exposure demonstrated an increase in survival rates from 29% in the placebo group to 97% in the treated group.

The administration of PLX- R18 as a prophylactic measure 24 hours before radiation exposure, and again 72 hours after exposure, resulted in an increase in survival rates, from 4% in the placebo group to 74% in the treated group.

The FDA previously cleared an Investigational New Drug application for PLX-R18 for the treatment of radiation sickness and granted it Orphan Drug Designation. This means that should a nuclear event take place, Pluri could use the drug to treat victims.

Pluri’s bioreactors for the cultivation of cell-based therapy products. (Courtesy/Michael Brikman)

In July 2023, Pluri was awarded a three-year $4.2 million contract by the US National Institutes of Health to continue to develop its novel treatment for deadly radiation sickness and to collaborate with the US Department of Defense’s Armed Forces Radiobiology Research Institute in Maryland.

As part of the contract, the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will fund final studies required to complete the biotech firm’s application for FDA approval to market its PLX-R18 therapy.

Pluri hopes that the approval would make it eligible for purchase by the US Strategic National Stockpile — the country’s repository of critical medical supplies — as a medical countermeasure for exposure to nuclear radiation.

The Technion is the only Israeli university in the top 100 and ranks 89th worldwide

The U.S. National Academy of Inventors (NAI) has ranked the Technion – Israel Institute of Technology  first in Israel and second in Europe for the number of U.S. patents approved in  2024, with 43 patents registered last year. The Technion is the only Israeli university on this prestigious list, placing 89th globally.

Rona Samler, general manager of T3 – the Technion’s commercialisation unit, stated:

“I am extremely proud of our ranking among the world’s top 100 universities and our first-place standing in Israel for the fourth consecutive year. This recognition is a testament to the excellence of Technion researchers in scientific and engineering innovation and the institution’s strength in translating ideas into research and research into world-changing technologies. This is one of the key ways the Technion makes a lasting impact on society and the economy.”

Patent registration in the U.S. enables academic institutions to transform groundbreaking technologies into competitive global products, significantly benefiting consumers and industries worldwide.

Dr. Paul Sanberg, president of the NAI, emphasised: “By recognising this crucial step in the commercialisation process, we highlight the role of intellectual property in benefiting inventors and institutions while encouraging the development of technologies with a potentially significant societal and economic impact.”

The NAI ranking is based on data from the United States Patent and Trademark Office (USPTO) for 2024 and includes 100 institutions and 9,600 patents.

Israeli medical startup AISAP, which is pioneering AI-driven diagnostics, has been recognised as one of the world’s most innovative and promising companies for 2025 by Fast Company. AISAP secured fourth place globally in the healthcare category, a remarkable achievement that underscores the international recognition of its groundbreaking technology and its impact on the future of medicine. One of their products, AISAP CARDIO, is the world’s first real-time AI-powered cardiac diagnostic platform. AISAP Co-founder Ehud Raanani is a Technion alumnus.

Autonomous Flying Cowboys Manage Livestock More Efficiently: Israeli tech startup BeeFree Agro has just delivered its first fleet of “autonomous flying cowboys” to a paying customer. The robots are eyes in the sky that will transform the way the world’s beef cattle are farmed. The drones supply a live feed for 30-minute missions over a ranch and provide high-resolution pictures that show the precise GPS location of every single cow, providing an exact count. Its first system went live in January in Brazil, where it currently manages around 3 million cattle. BeeFree Agro Co-founder and COO Dvir Cohen is a Technion alumnus.

The Woman Behind the Billion-Dollar Brain Surgery Breakthrough:Technion alumna Nora Nseir, founder and co-CEO of Nurami Medical, was recently featured by CTech in an informative Q&A. Nora speaks about founding the company with her partner, Dr. Amir Bahar, their products (which include an internal gel seal that degrades within the body once a wound is healed and a suture-free adhesive that can replace damaged meningeal tissue until new tissue grows), funding rounds, and more.

Ten Israeli-founded firms were chosen for this year’s Fast Company Most Innovative Companies lists in specific categories, three of which have Technion connections. In the enterprise category, aiOla is featured for helping industry reduce paper forms via AI and using AI-powered speech recognition for tasks like vehicle safety. In the security category, Dazz was featured for using AI to help find and fix critical issues within cloud infrastructures. And Silverfort, also in the security category, was featured for protecting every login and account in an enterprise. aiOla COO Alon Peleg, Dazz Co-founder and CEO Merav Bahat, and Silverfort Co-founder and CTO Yaron Kassner are all Technion alumni.

Conversational AI pioneer aiOla is cited for “rescuing legacy industries from paper forms via AI,” using AI-powered speech recognition for tasks like vehicle safety inspections in more than 120 languages spoken in various accents.

Dazz appears in the security category “for using AI to help find and fix critical issues within cloud infrastructures.” The startup was acquired by Israeli unicorn Wiz at the end of 2024 for approximately $450 million. (Wiz itself is in the midst of acquisition by Alphabet for a record $32 billion.)

Silverfort also won a place on the security category list, for “protecting every login and account in an enterprise.” The company focuses on identity security, integrating authentication into a single, easy-to-install platform that can instantly block compromised accounts, trigger multifactor authentication, and accelerate remediation time.